Active Biotech: Interim report January - March 2017

Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
• The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
• Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)

ANYARA     

• Project proceeding according to plan

Tasquinimod, paquinimod and SILC

• Out-licensing activities are continuing
• The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
• Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
• Product patent for SILC substances granted by the European Patent Office

Financial summary

• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

The report is also available at www.activebiotech.com.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/e19e9aad-c392-4cf4-b127-da952a463a0f